Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Jamp Pharma Corporation

Home Clinical Trial Sponsors and OrganizationsJamp Pharma Corporation

Jamp Pharma Corporation

8065 Aitken Rd, Chilliwack, British Columbia, Canada

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

6

3 active

Approvals

1009

Total approvals

Agencies

1

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 3

5

83.3%

Trial Status Distribution

Active, not recruiting

2

33.3%

Completed

3

50.0%

Not yet recruiting

1

16.7%

Clinical Trials

Trials sponsored by this organization (6)

To understand the safety and outcome of Tacrolimus ointment 0.1% in patients suffering from Atopic dermatitis

Active, not recruiting

To evaluate the efficacy and tolerability of diclofenac diethylamine 1.16% w/w gel in patients with acute localised muscle or joint injuries

Active, not recruiting

To understand the safety and outcome of Tacrolimus ointment 0.1% in patients suffering from Atopic dermatitis

Dec 2023450 participants

To evaluate the efficacy and tolerability of diclofenac diethylamine 1.16% w/w gel in patients with acute localised muscle or joint injuries

Mar 2023255 participants

The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.

Jan 2023324 participants

A clinical study to test a Diclofenac Gel in comparison with another reference gel and an inert gel for Pain Relief and Safety in Fresh Outer Ankle Sprains (ankle twists)

Not yet recruiting

May 2026360 participants

Approvals

Approvals by Agency

CANADA

Health Canada

1009

Approvals

Recent Approvals

JAMP TOBRAMYCIN / DEXAMETHASONE

JAMP METRONIDAZOLE GEL

JAMP DOXEPIN TABLETS

JAMP DOXEPIN TABLETS

JAMP-MIRTAZAPINE

JAMP RAMIPRIL CAPSULES

JAMP RAMIPRIL CAPSULES

JAMP SODIUM POLYSTYRENE SULFONATE

News

Kashiv BioSciences and JAMP Pharma Launch Neutropenia Biosimilars in Canada

- Kashiv BioSciences and JAMP Pharma have commercially launched Pexegra and Filra, biosimilar alternatives to Neulasta and Neupogen respectively, in the Canadian market. - Both biosimilars are indicated for treating neutropenia in cancer patients undergoing chemotherapy, with Pexegra reducing infection incidence and Filra addressing severe neutropenia conditions. - The launch marks JAMP Pharma's entry into oncology biosimilars through its BioJAMP division, expanding treatment options for Canadian patients. - The products are available as pre-filled syringes with safety features and represent part of JAMP's commitment to providing affordable biosimilar alternatives in Canada.

On this page

Overview
Clinical Trials6
Approvals1009
News1

Back to Organizations